Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?

Authors

  • John C. Hoefs M.D.,

    1. Division of Gastroenterology, University of California, Irvine, CA
    Search for more papers by this author
    • Potential conflict of interest: Dr. Hoefs is on the speaker's bureau of Gilead and Roche. Dr. Morgan is on the speakers' bureau of and received grants from Schering-Plough. He is a consultant for, is on the speakers' bureau of, and received grants from Hoffmann-La Roche.

  • Timothy R. Morgan M.D.

    Corresponding author
    1. Gastroenterology Section, VA Long Beach Healthcare System, Long Beach, CA
    • 5901 East Seventh Street, Long Beach, CA 90822
    Search for more papers by this author
    • Potential conflict of interest: Dr. Hoefs is on the speaker's bureau of Gilead and Roche. Dr. Morgan is on the speakers' bureau of and received grants from Schering-Plough. He is a consultant for, is on the speakers' bureau of, and received grants from Hoffmann-La Roche.

    • fax: 562-826-8023.


  • See Article on Page 1688.

Ancillary